Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
Hummingbird and Dartmouth's Geisel School of Medicine to Co-Host VISTA Symposium
Hummingbird to Present Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
LONDON and SINGAPORE, Oct. 23, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced presentation of positive clinical data for the dose escalation part of the HMBD-001 Phase I/IIa trial (NCT05057013) at the European Society for Medical Oncology Congress 2023 (ESMO 2023). The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
Endeavor signs $430M deal for Hummingbird’s HER3-targeted ADC
SAN FRANCISCO, HOUSTON and SINGAPORE, May 15, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma (sqNSCLC).
Singapore-based biotechnology company Hummingbird Bioscience has partnered with Merck to evaluate its HER3-targeting antibody HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma (sqNSCLC).
SAN FRANCISCO, HOUSTON and SINGAPORE, May 8, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023™.
George Clinical, a global CRO, initiated preparations in Australia for two Phase 1b oncology trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer.